AstraZeneca to buy China-based Gracell Biotechnologies in $1.2 billion deal
AstraZeneca has carefully maneuvered through the complex pharmaceutical market, announcing intentions to pay up to $1.2 billion to purchase Gracell Biotechnologies.
Source: techstory.in